Engage with Annovis Bio at Their Upcoming Webinar
Join us for an exciting opportunity as Annovis Bio, Inc. (NYSE: ANVS), a pioneering company in clinical-stage therapies for neurodegenerative diseases, prepares to host a live webinar designed to enlighten audiences about their cutting-edge advancements. Maria Maccecchini, Ph.D., the President and CEO, will lead the discussion, providing updates on the company's progress and answering audience questions.
Details of the Live Webcast
The live webinar is scheduled, bringing together shareholders, patients, investigators, and anyone interested in brain health. Attendees can register for this engaging event:
- Date: June 24, 2025
- Time: 4:30 PM EDT
- Registration: Join us to learn more about the latest developments at Annovis.
During the session, Dr. Maccecchini will dive into the ongoing pivotal Phase 3 trials focusing on early Alzheimer's disease and share insights on the FDA's feedback regarding the ongoing Parkinson's disease program. The event will include a concise presentation followed by a valuable Q&A session where participants can directly interact with the CEO and pose their queries.
Innovative Solutions for Neurodegeneration
As a company specializing in the development of revolutionary therapies for neurodegenerative disorders, Annovis is at the forefront of addressing conditions like Alzheimer’s and Parkinson’s disease. Their unique approach is tailored to target multiple neurotoxic proteins, aiming to restore cognitive functions and enhance the overall quality of life for those affected.
Building Community Engagement
The forthcoming webinar is not just a presentation but a vital forum for engagement. Stakeholders and advocates are encouraged to submit their questions in advance to ensure the discussion is robust and relevant. Interaction fosters transparency between the company and its community, which is crucial in the rapidly evolving field of neurodegenerative research.
About Annovis Bio
Founded with the vision to tackle the complexities of neurodegeneration, Annovis Bio operates with a dedication to innovation. Their ongoing efforts and research are not only geared towards developing drugs but also enhancing the understanding of these debilitating diseases.
For those looking to stay informed, Annovis has made it easy to receive updates and vital information about their activities. Shareholders and interested parties can sign up for press releases and news through their Email Alerts. This initiative keeps everyone connected to the latest developments, ranging from clinical trials to corporate announcements.
Contact Information
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
Website: www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
Email: ir@annovisbio.com
Frequently Asked Questions
What is the purpose of the Annovis webinar?
The webinar aims to inform attendees about Annovis' advancements in neurodegenerative disease therapies and allow for direct engagement with the CEO.
Who can attend the Annovis webinar?
The webinar is open to shareholders, patients, researchers, and anyone interested in neurodegenerative diseases.
How can attendees submit questions for the webinar?
Participants are encouraged to send their questions in advance via email to ensure they are addressed during the live Q&A.
What is Annovis' focus in research and development?
Annovis focuses on developing therapies for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, targeting neurotoxic proteins to improve brain function.
Where can I find more information about Annovis Bio?
Additional information can be gathered from Annovis' website and by subscribing to their email alerts for news and updates.
